Beryllium Disease and EEOICPA
Workers from facilities covered by EEOICPA who suffer from beryllium diseases may be eligible for compensation under the EEOICPA under Part B and Part E. Under Part B workers with Chronic Beryllium Disease (CBD) or beryllium sensitivity are covered. Under Part E workers may be covered for illnesses caused by beryllium as a toxic substance. Employees of beryllium vendors are not eligible for benefits under Part E of the EEOICPA. However, uranium miners, millers, and ore transporters as defined under Section 5 of the Radiation Exposure Compensation Act (RECA) may be eligible for Part E benefits.
There are separate requirements that must be met depending on when the worker first was diagnosed with Chronic Beryllium Disease.
1. If CBD was diagnosed before January 1, 1993, the medical documentation must include exposure to beryllium, plus three of the five following criteria:
- Immunologic tests showing beryllium sensitivity (skin patch test or beryllium blood test
- Characteristic chest X-ray or computed tomography (CT) abnormalities
- Restrictive or obstructive lung physiology testing or diffusing lung capacity defect
- Lung pathology consistent with CBD
- Clinical course consistent with a chronic respiratory disorder
2. If CBD was diagnosed on or after January 1, 1993, the medical documentation must include: an abnormal beryllium lymphocyte proliferation test (BeLPT), or an abnormal beryllium lymphocyte transformation test (BeLTT), performed on either blood or lung lavage cells; lung pathology consistent with CBD; plus any of the following:
Useful Documents on Beryllium Disease
Workers and Managers/Supervisors, Beryllium Health Risk Communication Task Force, April 2002